Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. BioNTech acquires T cell therapy-focused Neon for $67m
  2. NICE cancer guidance: good news for Ibrance and Lynparza
  3. FDA grants Clovis’ Rubraca fast track designation for prostate cancer
  4. Japan approves ViiV’s two drug regimen Dovato for HIV
  5. MorphoSys and Incyte sign $900m deal for B-cell malignancies drug

Latest Content

BioNTech acquires T cell therapy-focused Neon for $67m

BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.

NICE cancer guidance: good news for Ibrance and Lynparza

The UK’s pricing regulator NICE decides whether new therapies are sufficiently cost-effective for NHS use. In its most recent publishing of guidance, NICE determined two oncology drugs – Pfizer’s Ibrance and AstraZeneca’s Lynparza – were promising, but for certain patient populations they should only be available through its managed-access scheme while further data is gathered. What explains this decision?

Case Study: Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top